Ascendis Pharma A/S (ASND) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) recently:

• 7/23/2026 – Ascendis Pharma A/S had its price target raised by Morgan Stanley from $256.00 to $275.00. They now have an “overweight” rating on the stock.
• 7/18/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/15/2026 – Ascendis Pharma A/S was upgraded by Weiss Ratings from “sell (d)” to “hold (c)”.
• 7/7/2026 – Ascendis Pharma A/S had its price target raised by Royal Bank Of Canada from $275.00 to $280.00. They now have an “outperform” rating on the stock.
• 7/4/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/20/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/9/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jean Jacques Bienaime acquired 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the transaction, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.